Deals Of The Week: Astellas/OSI; Pfizer/Washington U; Sanofi/Nepentes ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com
You may also be interested in...
Pfizer/Washington U. Tie-Up Involves Reprofiling Of Existing Compounds
Under five-year collaboration, university researchers will have access to more than 500 Pfizer compounds and their clinical and preclinical data.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials